Answers are grounded in this paper and cite their sources.
Introduction: We aimed to evaluate the reporting quality of randomized controlled trials (RCTs) for surgical interventions in stone disease across 2002–2023, extending two earlier reviews of the literature with a new 2018–2023 cohort. Previous assessments of the reporting quality of RCTs in nephrolithiasis have shown suboptimal adherence. Methods: Building on two prior studies, we conducted a comprehensive literature search for RCTs assessing surgical stone interventions. Four independent reviewers performed data abstraction in duplicate. Reporting quality was assessed using the 25-item Consolidated Standards of Reporting Trials (CONSORT) checklist, with each study scored from 0−25; the primary outcome was the mean score. Scores were compared across four time periods (2002–2006, 2007−2011, 2012–2017, and 2018–2023) using ANOVA in SPSS version 29. Results: Three hundred and thirty-one studies met inclusion criteria (2002−2006: 38, 2007−2011: 64, 2012−2017: 101, and 2018−2023: 128). The mean ± standard deviation CONSORT summary scores for the four time periods were 11.4±2.3, 12.1±2.4, 12.7±2.9, and 16.1±3.2, respectively (p<0.001). Reporting rates were lowest for reporting ancillary analyses (10.9%) and implementation of randomization (14.0%). Notable improvements over time (2002−2006 vs. 2007−2011 vs. 2012−2017 vs. 2018−2023) were seen for trial registration (0% vs. 0% vs. 13.9% vs. 40.6%, p<0.001) and funding source (5.1% vs. 9.2% vs. 13.9% vs. 62.5%, p<0.001), respectively. Conclusions: The reporting quality of RCTs of surgical interventions for nephrolithiasis has improved, but critical methodologic domains remain underreported. Greater awareness of transparent trial reporting is needed.
No takes yet. Share an insight, caveat, or question.
Vogel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: